Novo Nordisk’s Wegovy weight loss drug has seen a meteoric rise in popularity. Nurphoto | Getty Images LONDON — The U.K.’s health regulator on Tuesday approved the use of Novo Nordisk‘s Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. The new approval from … Read more
Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate. The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market. Roche shares jumped in … Read more
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Novo Nordisk‘s blockbuster diabetes drug Ozempic may have more to offer beyond … Read more
Aykut Karahan | Istock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Several drugmakers are hurrying to capitalize on one of the next major innovations coming to the booming weight loss drug market: effective, convenient and potentially affordable obesity pills. Most of the … Read more
My top 10 things to watch Thursday, July 11 The S & P 500 and Nasdaq , both on seven-session winning streaks, were looking lower after more records. The June consumer price index year over year came in around its lowest inflation level in more than three years. Stock futures were initially higher on the … Read more
Sopa Images | Lightrocket | Getty Images Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw “encouraging” data in an ongoing early-stage trial. The company evaluated several once-daily formulations of the drug and identified one with “the most favorable profile.” Pfizer said it … Read more
CNBC’s Jim Cramer on Wednesday gave his take on Hims & Hers Health, a digital platform that offers telehealth services, particularly for sexual health, mental health, weight loss and skin care. Hims & Hers also provides direct-to-consumer treatments for conditions like erectile dysfunction and hair loss. Cramer suggested it might be worth starting a position … Read more
FTC Chairwoman Lina Khan testifies during the House Appropriations Subcommittee on Financial Services and General Government hearing titled “Fiscal Year 2025 Request for the Federal Trade Commission,” in Rayburn Building on Wednesday, May 15, 2024. Tom Williams | CQ-Roll Call, Inc. | Getty Images The Federal Trade Commission is planning to sue three large U.S. … Read more
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The S & P 500 and Nasdaq climbed to new records Tuesday, extending their winning streaks to five sessions in a row. Mega-cap tech once again led the way. Goldman … Read more
Traders work on the floor of the New York Stock Exchange, June 14, 2023. Spencer Platt | Getty Images This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You … Read more
